| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.10923 |
| P698 | PubMed publication ID | 12589646 |
| P50 | author | Valerie W Rusch | Q51775643 |
| P2093 | author name string | Maureen F Zakowski | |
| Marc Ladanyi | |||
| Peter B Illei | |||
| P2860 | cites work | p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology | Q73152515 |
| p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma | Q73429281 | ||
| Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining | Q73486933 | ||
| Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions | Q74006451 | ||
| The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses | Q74128428 | ||
| The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma | Q74185593 | ||
| E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless | Q74622958 | ||
| Diagnostic problems in serous effusions | Q77083445 | ||
| Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review | Q77204685 | ||
| Cytology: screening or diagnostic tool? | Q77726668 | ||
| Numerical abnormalities of chromosomes 7, 18, and x in precancerous breast disease defined by fluorescent in situ hybridization | Q83167936 | ||
| A cell cycle regulator potentially involved in genesis of many tumor types | Q28251933 | ||
| Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest | Q28270478 | ||
| The separation of benign and malignant mesothelial proliferations | Q33389630 | ||
| p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections | Q33389929 | ||
| Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update | Q33681712 | ||
| Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma | Q34293053 | ||
| Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions | Q38473427 | ||
| p53 expression is common in malignant mesothelioma | Q44259985 | ||
| The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining | Q47685920 | ||
| Calretinin: A Novel Immunocytochemical Marker for Mesothelioma | Q60609644 | ||
| A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma | Q63548148 | ||
| Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium | Q67989298 | ||
| Markers for metastatic adenocarcinoma in serous effusion specimens | Q71675522 | ||
| Significance of epithelial membrane antigen in the work‐up of problematic serous effusions | Q71811949 | ||
| The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma | Q71975039 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diagnostic marker | Q129938486 |
| P304 | page(s) | 51-56 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions | |
| P478 | volume | 99 |
| Q80788485 | 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis |
| Q47624664 | A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma |
| Q92383067 | A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations |
| Q46024349 | BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions. |
| Q90671775 | Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer |
| Q43191497 | CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival |
| Q92859970 | Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma |
| Q90753927 | Current applications of molecular testing on body cavity fluids |
| Q46644119 | Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16. |
| Q36467429 | Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue |
| Q34759870 | Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas |
| Q80462587 | Early cytological diagnosis of diffuse malignant mesothelioma of the peritoneum: a case report |
| Q90346713 | Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma |
| Q37281015 | Expression of cancer-associated molecules in malignant mesothelioma |
| Q34337640 | FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma |
| Q28389535 | Factors that impact susceptibility to fiber-induced health effects |
| Q33290349 | Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. |
| Q95648117 | HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion |
| Q92969758 | Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma |
| Q38260520 | Is the cytodiagnosis of mesothelioma any easier these days? |
| Q49232092 | Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. |
| Q35903683 | Malignant effusions: from diagnosis to biology |
| Q90084125 | Methionine metabolism in health and cancer: a nexus of diet and precision medicine |
| Q34602201 | Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology |
| Q27853144 | Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. |
| Q37975136 | Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy |
| Q92617808 | Pre-analytical issues in effusion cytology |
| Q89967071 | Preclinical Models of Malignant Mesothelioma |
| Q33390251 | Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas |
| Q97551661 | Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology |
| Q47133389 | The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma |
| Q33658238 | The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club |
| Q38012418 | The diagnostic and research applications of flow cytometry in cytopathology |
| Q51736026 | The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. |
| Q90261068 | The utilization and utility of immunostains in body fluid cytology |
| Q36755500 | Update on the molecular biology of malignant mesothelioma |
| Q38843154 | Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations |
| Q39404727 | YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. |
Search more.